As a result, current clinical guidelines for T2DM, kidney disease, and cardiovascular care strongly recommend the use of GLP-1RAs and SGLT2is in patients with T2DM who have, or are at high risk for, atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD)
You may simply not feel thirsty, even when your body badly needs water
Med (Kaunas) 61:450
DPP-4 inhibitors-renoprotection in diabetic nephropathy
In eukaryotes, GSTs are divided according to their cellular localization into at least three major families of proteins, namely cytosolic GSTs, mitochondrial GSTs and microsomal GSTs 1,2,6
GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally
